title: A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.
abstract: Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with FIP1L1-PDGRFA rearrangement and 5/17 without, P = 0.006), most after 2 weeks of 100 mg/d imatinib. The maximum imatinib dose had no effect in early unresponsive patients. Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset.
authors.affiliation: Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy.
authors.forename: Tamara
authors.initials: T
authors.lastname: Intermesoli
authors.forename: Federica
authors.initials: F
authors.lastname: Delaini
authors.forename: Sara
authors.initials: S
authors.lastname: Acerboni
authors.forename: Silvia
authors.initials: S
authors.lastname: Salmoiraghi
authors.forename: Orietta
authors.initials: O
authors.lastname: Spinelli
authors.forename: Vittoria
authors.initials: V
authors.lastname: Guerini
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Vannucchi
authors.forename: Silvia
authors.initials: S
authors.lastname: Mappa
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rossi
authors.forename: Valentina
authors.initials: V
authors.lastname: Rossi
authors.forename: Eros
authors.initials: E
authors.lastname: Di Bona
authors.forename: Simona
authors.initials: S
authors.lastname: Paratore
authors.forename: Alessandra
authors.initials: A
authors.lastname: Carobbio
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
authors.forename: Renato
authors.initials: R
authors.lastname: Bassan
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004804:Eosinophils / Q000473:pathology; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D010879:Piperazines / Q000008:administration & dosage* / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D016896:Treatment Outcome; D055815:Young Adult; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
chemical_list: D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha